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ABSTRACT
Background: There is growing interest in the
potential utility of real-time PCR in diagnosing
bloodstream infection by detecting pathogen DNA
in blood samples within a few hours. SeptiFast
is a multipathogen probe-based real-time PCR
system targeting ribosomal DNA sequences of
bacteria and fungi. It detects and identiﬁes the
commonest pathogens causing bloodstream infection
and has European regulatory approval. The
SeptiFast pathogen panel is suited to identifying
healthcare-associated bloodstream infection acquired
during complex healthcare, and the authors report
here the protocol for the ﬁrst detailed health-
technology assessment of multiplex real-time PCR in
this setting.
Methods/design: A Phase III multicentre
double-blinded diagnostic study will determine the
clinical validity of SeptiFast for the rapid detection of
healthcare-associated bloodstream infection, against
the current service standard of microbiological
culture, in an adequately sized population of critically
ill adult patients. Results from SeptiFast and standard
microbiological culture procedures in each patient
will be compared at study conclusion and the metrics
of clinical diagnostic accuracy of SeptiFast determined
in this population setting. In addition, this study
aims to assess further the preliminary evidence that
the detection of pathogen DNA in the bloodstream
using SeptiFast may have value in identifying
the presence of infection elsewhere in the body.
Furthermore, differences in circulating immune-
inﬂammatory markers in patient groups differentiated
by the presence/absence of culturable pathogens
and pathogen DNA will help elucidate further the
patho-physiology of infection developing in the
critically ill.
Ethics and dissemination: Ethical approval
has been granted by the North West 6 Research
Ethics Committee (09/H1003/109). Based on the
results of this ﬁrst non-commercial study, independent
recommendations will be made to The Department
of Health (open-access health technology assessment
report) as to whether SeptiFast has sufﬁcient
clinical diagnostic accuracy to move forward to
efﬁcacy testing during the provision of routine
clinical care.
BACKGROUND
Healthcare-associated infection (HCAI) is
a major cause of mortality and morbidity and
represents a massive burden on resources
with the national audit ofﬁce in England
alone estimating annual costs in excess of £1
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ARTICLE SUMMARY
Article focus
- To highlight the unmet need for accurate and
rapid infection diagnostics in the setting of life-
threatening infection.
- To describe the systematic plans of a clinical
diagnostic validity study of a new real-time PCR
technology, designed to detect circulating path-
ogen DNA associated with bloodstream infection.
- To describe the clinical standards for sepsis and
healthcare-associated infection diagnosis and
identify how these standards will be utilised to
determine the clinical validity of the new real-
time PCR test in critically ill patients.
Key messages
- The study will provide the ﬁrst independent,
systematic, clinical validity study of real-time
PCR technologies in the focused setting of
suspected life-threatening healthcare-associated
infections during the provision of routine emer-
gency critical care.
- Based on the results of this study, independent
recommendations will be made to the UK’s
Department of Health as to whether the real-
time PCR technology has sufﬁcient clinical
diagnostic accuracy to move forward to efﬁcacy
testing during the provision of routine clinical
care.
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Open Access Protocolbillion.
1 Improved measures to prevent and treat HCAI
are currently among the very highest priority areas for
many health services worldwide. The critically ill, despite
signiﬁcant advances in their supportive care, remain at
high risk of developing severe infections and organ
failure, which carry a high mortality and healthcare
costs.
23Conﬁrmation of infection in this setting depends
on identiﬁcation of live micro-organisms (pathogens) by
microbiological culture of samples such as blood.
4
However, culture routinely takes several days before
a positive result is available and at least 5 days to deter-
mine that a specimen is culture-negative.
5 This temporal
separation between initial clinical suspicion and conﬁr-
mation of infection routinely results in the early and
sustained application of potent broad-spectrum antibi-
otics and antifungal agents aimed at covering the most
likely pathogens as a ‘safety ﬁrst’ strategy because a delay
in appropriate antimicrobial therapy is associated with
increased mortality.
6 The increased and inappropriate
use of antibiotics, which is an inevitable consequence, is
associated with the development of multiresistant strains
of bacteria (eg, MRSA) and superinfection with Clos-
tridium difﬁcile.
1 By the nature of complex healthcare,
overwhelming inﬂammation of the body is a common
occurrence in critically ill patients and is not always
caused by infection
7 (eg, it may be caused by trauma,
blood transfusion or pancreatitis), leading further to the
inappropriate use of antibiotics owing to the lack of time-
critical biomarkers of infection. There is therefore an
urgent need to develop techniques that can provide
appropriate diagnostic accuracy within hours of clinical
signs appearing and so allow more informed use of
antibiotic therapy at an early stage.
89
There is growing interest in the potential of real-time
PCR technology to address this problem based on the
ability of this technique to detect minute amounts of
pathogen DNA in patient blood samples with results
available within 4e6h .
10 Proof-of-concept studies have
focused on two approaches, either the use of PCR
with universal probes to show the presence of bacterial
or fungal DNA, with species identiﬁcation dependent
on later sequencing of the PCR products, or using
strain-speciﬁc probes that provide a direct readout of the
pathogen species present.
10 Intuitively, the latter
approach would seem to have the greatest clinical utility.
While the analytical sensitivity and speciﬁcity of these
approaches for the detection of pathogen DNA in blood
are recognised, there remains an acknowledged lack of
clinically driven research to assess their clinical validity.
This has been due in part to the lack of standardised
technology platforms that meet accepted regulatory
standards for clinical diagnosis. SeptiFast, manufactured
by Roche Diagnostics, and run on their real-time PCR
instrument (the LightCycler 2), was the ﬁrst real-time
PCR-based system to gain a Conformite ´ Europe ´enne
(CE) mark for pathogen detection in suspected blood-
stream infection.
11 The system uses a multiplex
approach in a single blood sample which allows the
detection of 25 of the most common pathogen species
causing bloodstream infection internationally (table 1),
and this panel is particularly well matched to the
common pathogens responsible for bloodstream HCAI
in critical care.
12 Identiﬁcation of the pathogens is based
on the use of species-speciﬁc probes targeting the
internal transcribed region between the 16S and 23S
ribosomal DNA sequence of bacteria and the 18S and
5.8S regions of the fungal genome. As part of the ﬁrst
stage of health-technology assessment (analytical validity
testing), SeptiFast has been extensively assessed at the
laboratory level on clinical isolates and shown to have
excellent analytical speciﬁcity.
11 Subsequently, data
(unpublished) from an EU registrational study, under-
taken as part of the CE-marking process, investigating 278
ICU patients from Denmark, Germany and Italy, claimed
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Strengths and limitations of this study
- The study is focused on a carefully delineated clinical cohort at
signiﬁcant risk of developing life-threatening infection.
- The study is non-commercial and has been planned system-
atically by a multidisciplinary team of experts and patient
representatives, working on behalf of the key stakeholders
within a nationalised healthcare system.
- Current clinical infection diagnosis standards may not have
a high diagnostic accuracy in all settings and with all infections.
- There is a documented high rate of broad-spectrum antimi-
crobial therapies delivered to critically ill patients empirically
which could confound the comparison between culture
methods and pathogen DNA-detection methods.
Table 1 Pathogens detectable using the LightCycler SeptiFast test
Gram-negative bacteria Gram-positive bacteria Fungi
Escherichia coli Staphylococcus aureus Candida albicans
Klebsiella (pneumoniae/oxytoca) Coagulase-negative staphylococci* Candida tropicalis
Serratia marcescens Streptococcus pneumonia Candida parapsilosis
Enterobacter (cloacae/aerogenes) Streptococcus sppy Candida glabrata
Proteus mirabilis Enterococcus faecium Candida krusei
Acinetobacter baumanni Enterococcus faecalis Aspergillus fumigatus
Pseudomonas aeruginosa
Stentrophomonas maltophilia
*Single probe detects a group of staphylococcal pathogens including Staphylococcus epidermidis and Staphylococcus haemolyticus.
ySingle probe detects a group of streptococcal pathogens including Streptococcus pyogenes, Streptococcus agalacticae and Streptococcus
mitis.
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sensitivity for real-time PCR compared with conventional
culture in patients with sepsis. More recently, a number
of multicentre investigator-led commercial clinical
observational studies have commenced reporting on
SeptiFast,
13 14 but to date no studies have investigated
systematically the clinical diagnostic accuracy of SeptiFast
in the setting of suspected HCAI.
The aim of this study, therefore, is to determine
the clinical validity of the use of real-time PCR-based
diagnostic technology for the rapid detection and iden-
tiﬁcation of healthcare-associated bloodstream infection
when compared with the current service standard
of microbiological culture, in an appropriately sized
population of adult intensive care patients being treated
within a regional Critical Care Network in the UK.
METHODS
Study objectives
The primary objectives are to determine the clinical
validity of the use of real-time PCR-based diagnostic
technology for the rapid detection and identiﬁcation of
healthcare-associated bloodstream infection against the
current service standard of microbiological culture in
a population of adult intensive-care patients within the
Greater Manchester Critical Care Network, UK, and
to assess further the preliminary evidence that the
detection of pathogen DNA in the bloodstream using
SeptiFast may have value in detecting the presence of
HCAI elsewhere in the body. The secondary objective is
to proﬁle differences in circulating immune-inﬂamma-
tory biomarkers in patients with or without circulating
culturable pathogen and/or micro-organism DNA
identiﬁed by real-time PCR.
Study design and sample size
This Phase III diagnostic trial
15 will evaluate the clinical
validity of SeptiFast for the identiﬁcation of healthcare-
associated bloodstream infection in the setting of UK
adult intensive-care practice when compared with the
current blood-culture standards. The study will recruit
from at least two intensive care units of the University-
afﬁliated tertiary referral centres within The Greater
Manchester Critical Care Network (Salford Royal NHS
Foundation Trust and The University Hospital of South
Manchester). Laboratory records show that, on average,
over 1200 requests are made in total from these two
intensive-care units for microbiological culture of blood
per annum, and our clinical pilot study indicated that
approximately 12% (95% CI 6% to 16%) will be diag-
nosed as having culture-conﬁrmed bloodstream infec-
tion.
16 Based on this event rate, a sample-size estimation
was performed, after Buderer,
17 which indicated that
a minimum sample size of 600 patients will be required
to be 95% sure that the pathogen-speciﬁc molecular test
has at least a 95% speciﬁcity and sensitivity when
compared with a culture-proven diagnosis. It is antici-
pated that this study can be delivered within the agreed
2-year funding period.
Patient selection
Inclusion criteria
Patients being managed in a designated intensive-care
bed, 16 years or older, developing a clinical suspicion of
bloodstream infection based a priori on meeting two
or more Systemic Inﬂammatory Response Syndrome
(SIRS) criteria,
18 developing at least 48 h after admission/
recent exposure to hospital care (deﬁning ‘healthcare-
associated’
19) will be eligible for inclusion in the study.
In the present study, the SIRS deﬁnition will be met if
two or more of the following clinical signs are present:
body temperature greater than 388C or less than 368C,
heart rate greater than 90 beats/min, high respiratory
rate (more than 20 breaths/min) or, on blood gas,
a Paco2 less than 32 mm Hg for spontaneously breathing
patients; or requirement for mechanical ventilation in
established critical illness, or white blood cell count
<4000 cells/mm
3 or >12000 cells/mm
3 or the presence
of more than 10% immature neutrophils.
Exclusion criteria
A patient will be excluded if they have been recruited
already into this study, or they are on a Care of the Dying
Pathway, or if consent from the patient is declined or,
where appropriate, assent from next of kin or Indepen-
dent Mental Capacity Advocate is not obtained. All such
patient exclusions will be recorded in a site-speciﬁc
screening log and summarised in the ﬁnal report.
Clinical research methodology
Identiﬁcation and recruitment of participants
Potential participants will be identiﬁed to the study
research nurse through the normal clinical surveillance
of patients by the multidisciplinary critical care teams.
Intensive-care patients, 16 years or older, developing
clinical suspicion of healthcare-associated bloodstream
infection as indicated by meeting the predetermined
SIRS criteria related to changes in heart rate, body
temperature, ventilation and white blood cell count will
be potential participants (as described above).
Since blood sampling for infection diagnosis is taken
as part of routine emergency care of these patients,
under international guidelines the sample has to be
taken within 1 h of suspecting infection.
4 Under these
circumstances, unless the patient has the capacity to
provide consent, we will adopt a process of deferred
assent where the research blood sample is taken as part
of routine care and permission sought from the
consultee or the Independent Mental Capacity Advocate
at each recruitment site for inclusion into the study.
In many cases, the potential participants will lack
capacity at study inception owing to the combination of
their overwhelming illness and therapeutic interventions
such as sedation. Therefore, assent will be sought from
their family members/friends (consultees). Every effort
will be made to seek out and consult the patient’s
designated consultee and conduct a formal assent as part
of the process which will include a participant/consultee
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research team and signed assent. A patient will not be
recruited if the designated consultee believes it is likely
to be against the views and wishes of that patient. It is our
experience that we can locate a designated consultee for
the majority of patient’s in our critical care network
within 72 h. However, from time to time, this may prove
impossible, and under such circumstances we will
approach the appropriate designated Independent
Mental Capacity Advocate.
Should the participant regain capacity during their
acute care hospitalisation, informed consent for inclu-
sion in the study will also be sought.
Laboratory-conﬁrmed diagnosis of bloodstream infection
Key to the success of this study will be the culture-based
laboratory conﬁrmed diagnosis of bloodstream infection
in our target population. We will use the consensus
deﬁnition of bloodstream infection utilised in our
Network for prevalence studies of HCAI.
19
Deﬁnition: Laboratory culture conﬁrmed bloodstream
infection must meet at least one of the following criteria:
Criterion 1: patient has a recognised pathogen cultured
from one or more blood cultures
Criterion 2: patient has systemic signs of infection
(deﬁned as meeting the SIRS criteria in the present
studydsee ‘Inclusion criteria’) and a common skin
contaminant (eg, diptheroids, Bacillus spp, Propionibacte-
rium spp, coagulase-negative staphylococci or micro-
cocci) as cultured from two or more blood cultures
drawn on separate occasions. Contamination of the
blood culture will be deﬁned when these common
skin species are otherwise present in culture outwith
Criterion 2.
Having identiﬁed a patient in the target population,
two blood samples of at least 20 ml each will be taken
sequentially from two separate sites.
5 Importantly, blood
from indwelling catheters must be avoided where
possible for the purposes of SeptiFast PCR analysis and
the associated blood culture, but may be used for the
analysis of other biomarkers of infection if necessary.
Any breach of this protocol will be recorded in the
Clinical Record Form (see below). An NHS-approved
aseptic non-touch technique will be used (http://www.
antt.org.uk/). These blood samples will be inoculated in
turn into paired culture bottles, labelled and processed
as per standard clinical practice in the participating
hospitals. Local audit, in association with quality-
improvement initiatives within the study sites, shows that
by using these methods we can keep blood-culture
contamination rates to below 5%. The blood-collection
process and automated culture methods used in each
centre, the quality-assurance accreditation from Clinical
Pathology Accreditation (UK) Ltd and any change in
methodology during the study period will be recorded
and reported. All culture bottles will enter the standard
clinical pathway in the respective services in the partici-
pating hospitals with subsequent reporting to clinical
service.
Research blood amples
A sample of whole blood equivalent to no more than
30 ml over and above that required for routine clinical
investigation will be sampled using an NHS-approved
non-touch technique (http://www.antt.org.uk/) and
collected into closed tubes containing ethylene diamine
tetra acetic acid (EDTA). This research sample and
routine sampling for microbiological culture analysis will
be performed by suitably trained clinical service staff
under the supervision of the senior clinical investigators,
and will be taken simultaneously. Each study participant
will contribute a single suspected bloodstream-infection
episode to the research study. Whole blood will be
collected using a closed system. Initial plasma separation
and blood storage will be performed near-patient (10 ml
of this whole blood will be used for plasma isolation
using standard techniques). All research samples will be
stored for up to a maximum of 72 h in a locked refrig-
erator within the individual critical care unit prior to
being transported to the Biomedical Facility research
laboratories at Salford Royal Hospital for further anal-
ysis. Collection and transportation of samples will be
coordinated by the research nurse at each site so that
a maximum storage time of 72 h at 48C is not exceeded
prior to sample analysis and/or freezing. Timings of this
process will be recorded with the samples to facilitate
quality-assurance measures for analysis.
Recording of clinical information
All potential participants who meet the study inclusion
criteria will be identiﬁed in a screening log in each
participating centre. Each included patient will be given
a unique study identiﬁcation number (ID). Any imme-
diately identiﬁable patient details will be recorded once,
on a Patients Identiﬁcation Form. Once a study ID is
assigned, a Case Record Form (CRF) will be opened and
the ID number copied to all pages in the CRF. Once the
ID number is entered on the CRF, it becomes a conﬁ-
dential document and must conform to the speciﬁed
Data Management procedures of the Study Sponsor
(Salford Royal NHS Foundation Trust). The CRF consists
of seven sections in order to record all the clinical
information required for the completion of the study
and acts as a point of reference for the research nurse to
ensure all clinical study stages are complete. These are:
1. Recruitment: requires conﬁrmation that the study
participant meets the inclusion criteria and summa-
rises the patient’s admission details including the last
7 days.
2. Trial sample data: summarises the sample data
allowing tracking of sample from the site from which
it was taken to transportation to the research
laboratory.
3. Consent/assent: acts as a checklist and point of
reference for the acquisition of consent or assent.
4. Patient observations:
< day 0: records a detailed snap-shot of the patient’s
clinical condition and treatment at the time of
the samples being taken. This includes general
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calculation of the critical care minimum dataset
and a focused overview considering the past
7d a y s ;
< antibiotics: a record of any antibiotics given from
7 days prior to sample being taken to study day 6;
< microbiology results: a record of any microbiology
results from the date the sample was taken;
< summary records of clinical progress of suspected
infection episode.
5. Patient surveillance: provides a continuous record of
relevant patient care up to and including study day 6.
This includes any signiﬁcant clinical events, general
observations and calculation of critical care minimum
dataset.
6. Patient surveillance summary: details the patients
outcome and any study related adverse incidences.
This section is also concluded with nurse signature of
completion.
7. Clinical adjudication: utilises the criteria set out in
the Prevalence Survey of Healthcare-associated Infec-
tions
19 to conclude and summarise the clinical
opinion regarding each suspected infection episode.
The Trial Steering Committee has agreed that this
adjudication will be performed in each participating
centre by two senior clinical practitioners who have
governance responsibility within their relevant service
for observing and reporting HCAI. No between-
centre adjudication will be performed, as this clinical
validity study is designed to observe routine clinical
practice (Phase 3 diagnostic study).
Laboratory research methodology
Once received at the research laboratory, blood samples
will be processed by one of two research scientists
who have received approved training by Roche Diag-
nostics UK for this purpose as follows: one portion of the
whole blood (5 ml) will be used for pathogen DNA
extraction and analysis by SeptiFast real-time PCR for
the identiﬁcation of pathogen DNA. The procedures for
pathogen DNA extraction, performing multipathogen
PCR and subsequent data analysis are set out in the
SeptiFast CE-marked kit (Roche Diagnostics) and will be
followed precisely. To ensure the validity of the data,
the SeptiFast system contains several built-in quality-
assurance processes. The results of each SeptiFast anal-
ysis will not be returned to routine clinical service and
will not be associated with any clinical or culture detail
until completion of the data-collection period. The
research laboratories within our Biomedical Facility are
not physically or operationally part of routine clinical
service, allowing research and clinically service to be
double-blinded during this study.
The plasma sample will be stored at 808C for subse-
quent analyses of inﬂammatory-immune biomarkers,
including pro- and counter-regulatory cytokine proﬁling
and procalcitonin assays. The ﬁnal portion of whole
blood (about 10e15 ml, depending on patient volume
yield) will be stored at 808C for future reanalysis of
pathogen DNA using alternative real-time PCR technol-
ogies that are currently under development by ourselves
and others (a stated requirement of the study funding
body).
Data-analysis plan
Summary diagnostic accuracy measures will be
computed for the SeptiFast PCR test compared with
laboratory culture-proven bloodstream infection,
including sensitivity, speciﬁcity, predictive values and
likelihood ratios, including 95% CIs. A similar analysis
will be performed using an ‘enhanced’ reference stan-
dard including culture-based identiﬁcation of infection
from clinical samples other than blood. All analyses of
diagnostic accuracy measures will be performed for all
participating hospitals combined, but allowing for
hospital as a stratifying factor (failure to allow for
hospital differences might lead to biased results owing
to confounding). In addition, sensitivity analyses will be
performed to investigate the possibility that blood
culture may not be an adequate reference standard
for infection diagnosis in these critically ill patients and
will include analyses using instrumental variables
20
such as replicate-independent cultures (and clinically
relevant cultures from other body sites), patient treat-
ment/response factors and circulating immune-inﬂam-
matory biomarkers. Finally, the immune-inﬂammatory
biomarker responses will be investigated in this cohort of
critically ill patients with the results of blood culture,
clinically relevant culture from other body sites and
circulating pathogen DNA as co-factors.
Sample and data security
Clinical samples
Detailed procedures are in place for the recording,
labelling and tracking of clinical samples in the clinical
and laboratory environments. Each sample will be
anonymised by labelling with a unique identiﬁer number
that will remain with the sample throughout the subse-
quent laboratory analysis and storage procedures. The
PCR research team will be blinded from all culture
results and clinical practice. Standard procedures for
transporting samples from the clinic to the laboratory
are in place. Laboratory processing of the samples will be
undertaken in the Biomedical Facility at Salford Royal,
which is a secure facility with restricted access. Where
required, samples will be stored in a dedicated 808C
freezer which is fully alarmed and has both manual and
automatic monitoring systems in place. All stored blood
and plasma samples will be destroyed at the end of
a 5-year period as agreed as part of the ethical review.
Data
Anonymised clinical and laboratory data for each patient
sample are recorded in CRF and Laboratory Case
Record forms respectively. Completed forms are photo-
copied once, and both documents are stored in a locked
ﬁling cabinet in secure locations at Salford Royal Foun-
dation Trust (Trials Ofﬁce) and University Hospital of
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Electronic data (eg, SeptiFast PCR data) will be stored
in a password-protected folder with electronic backup of
the contents of the folder to an encoded portable hard
drive on the last working day of each month. Paper
copies of key electronic data will also be stored as above.
Serious adverse events
The procedure of collecting an additional blood sample
during routine sampling for blood culture analysis is
not usually associated with any signiﬁcant increased risk
to patients or their carers. Standard operating proce-
dures are in place to cover all aspects of blood sampling,
storage, transportation and laboratory analysis to ensure
no signiﬁcant risk to any of the research staff associated
with this study. During the period of clinical data
monitoring (7 days), any serious adverse incident
reported within each participating centre’s statutory
reporting system will be reported to the Trial Sponsor by
the Principal Investigator at each site in association with
the Chief Investigator.
Regulatory/ethical approval
The Medicines and Healthcare products Regulatory
Agency has agreed that this study does not require their
formal approval, because it involves the observation of
a CE-marked assay performance during routine clinical
care, and that the results of the assay within this study
will not be used to inﬂuence clinical care. In addition,
this study has received favourable ethical opinion from
the North West 6 Research Ethics Committeed
Reference No: 09/H1003/109. R&D approval has been
granted by the study Sponsor, Salford Royal NHS
Foundation Trust (215ETt (25733/GM)).
Trial Steering Committee
A Trial Steering Committee has been appointed by the
National Institute for Health Research Health Tech-
nology Assessment programme, including an indepen-
dent chair and representation from patients recovering
from critical illness, the Investigators and Trial Sponsor
(Salford Royal NHS Foundation Trust), and have already
met in advance of the study commencement, approving
this protocol. Future regular meetings have been
planned during the course of this study to oversee
progress and adherence to regulatory and governance
research frameworks within the NHS.
Peer-review and funding
This study has been peer-reviewed and supported through
the Health Technology Assessment programme of the
National Institute of Health Research; grant number and
trial registration National Institute for Health Research
Health Technology Assessment 08/13/16.
DISCUSSION
Blood-culture technology is at the centre of evidence-
based guidelines for the investigation and treatment of
critically ill patients with suspected bloodstream infection.
While culture has been reﬁned over the last century, it
remains insufﬁciently time-critical and cannot assist with
early management decisions, inevitably resulting in
wasteful and potentially dangerous overtreatment with
antimicrobial chemotherapy. PCR-based technologies
have become standard laboratory technologies over the
last two decades and could deliver real opportunity in
terms of sensitivity and speed in the clinical setting of life-
threatening infection in critical care. Unfortunately, there
is a paucity of clinical translation, and formal health-
technology assessment is lacking. SeptiFast is the ﬁrst CE-
marked assay that has yet to be independently assessed in
a systematic study involving a clearly deﬁned clinical
population of critically ill patients suspected of devel-
oping healthcare-associated bloodstream infection. This
protocol describes the ﬁrst independent clinical validity
study of SeptiFast in the setting of suspected healthcare-
associated sepsis in critical care. Based on the results of
this non-commercial study, independent recommenda-
tions will be made to National Health Service providers as
to whether SeptiFast has sufﬁcient clinical diagnostic
accuracy to move forward to efﬁcacy and effectiveness
testing during the provision of routine critical care. The
present study therefore represents a crucial phase of
detailed independent health technology assessment
of the ﬁrst multiplex real-time PCR technique aimed at
helping deliver more effective care to critically ill patients
internationally.
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